靶向生长分化因子15-生长分化因子15受体-RET受体复合物的两侧：实现体重稳态的新方法。
Targeting both sides of the GDF15-GFRAL-RET receptor complex: A new approach to achieve body weight homeostasis.
作者信息
Li Fei, Ruan Xiongzhong, Min Le
机构信息
The Editorial Office of Genes & Diseases, Chongqing Medical University, Chongqing, China.
John Moorhead Research Laboratory, Centre for Nephrology, University College London, London, UK.
出版信息
Genes Dis. 2017 Nov 21;4(4):183-184. doi: 10.1016/j.gendis.2017.11.004. eCollection 2017 Dec.
Obesity is a chronic, complex disease, which is associated with several comorbidities, including diabetes mellitus, hypertension, and cardiovascular diseases. It is estimated that the prevalence of obesity among both adults and children nearly tripled between 1975 and 2016, highlighting a huge unmet treatment need. However, the currently available anti-obesity drugs have serious side effects, which limit their long-term use. The finding that the newly-identified brain GDF15-GFRAL-RET receptor signaling complex is involved in stress/disease-induced anorexia will certainly impact our knowledge of body weight homeostasis under healthy and disease conditions. Based on this breakthrough, a new class of GFRAL/RET-based drugs is highly anticipated for the treatment of obesity, as well as cancer-induced cachexia.
肥胖是一种慢性、复杂的疾病，与多种合并症相关，包括糖尿病、高血压和心血管疾病。据估计，1975年至2016年间，成人和儿童肥胖的患病率几乎增长了两倍，凸显出巨大的未满足治疗需求。然而，目前可用的抗肥胖药物有严重的副作用，限制了它们的长期使用。新发现的大脑生长分化因子15（GDF15）-GFRAL-RET受体信号复合物参与应激/疾病诱导的厌食症，这一发现必将影响我们对健康和疾病状态下体重稳态的认识。基于这一突破，人们高度期待一类新型的基于GFRAL/RET的药物用于治疗肥胖症以及癌症引起的恶病质。
Zotero 插件